CN118401254A - Kras g12d抑制剂与shp-2抑制剂的组合疗法 - Google Patents

Kras g12d抑制剂与shp-2抑制剂的组合疗法 Download PDF

Info

Publication number
CN118401254A
CN118401254A CN202280077626.5A CN202280077626A CN118401254A CN 118401254 A CN118401254 A CN 118401254A CN 202280077626 A CN202280077626 A CN 202280077626A CN 118401254 A CN118401254 A CN 118401254A
Authority
CN
China
Prior art keywords
inhibitor
shp
kras
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280077626.5A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔·哈林
詹姆斯·盖尔·克里斯滕森
薇琪·鲍卡特
彼得·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN118401254A publication Critical patent/CN118401254A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280077626.5A 2021-10-05 2022-10-04 Kras g12d抑制剂与shp-2抑制剂的组合疗法 Pending CN118401254A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252561P 2021-10-05 2021-10-05
US63/252,561 2021-10-05
PCT/US2022/045623 WO2023059598A1 (en) 2021-10-05 2022-10-04 Combination therapies of kras g12d inhibitors with shp-2 inhibitors

Publications (1)

Publication Number Publication Date
CN118401254A true CN118401254A (zh) 2024-07-26

Family

ID=85803689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280077626.5A Pending CN118401254A (zh) 2021-10-05 2022-10-04 Kras g12d抑制剂与shp-2抑制剂的组合疗法

Country Status (6)

Country Link
US (1) US20240423984A1 (https=)
EP (1) EP4412719A4 (https=)
JP (1) JP2024540839A (https=)
KR (1) KR20240073114A (https=)
CN (1) CN118401254A (https=)
WO (1) WO2023059598A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024543879A (ja) * 2021-11-24 2024-11-26 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ変異型タンパク質の小分子阻害剤
JP2025518795A (ja) * 2022-06-03 2025-06-19 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
JP2025523101A (ja) * 2022-07-12 2025-07-17 メッドシャイン ディスカバリー インコーポレイテッド ピペラジン架橋置換複素環ピリミジン系化合物
AU2024329738A1 (en) * 2023-08-22 2026-04-09 Sanofi 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4225383A4 (en) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES
WO2022187528A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline amine derivatives as kras inhibitors
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors

Also Published As

Publication number Publication date
US20240423984A1 (en) 2024-12-26
WO2023059598A1 (en) 2023-04-13
JP2024540839A (ja) 2024-11-06
EP4412719A4 (en) 2025-08-13
EP4412719A1 (en) 2024-08-14
KR20240073114A (ko) 2024-05-24

Similar Documents

Publication Publication Date Title
CN118382459A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
CN118401254A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
CN113164418A (zh) 组合疗法
JP7546549B2 (ja) 組み合わせ療法
US12527795B2 (en) Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
EP3849537B1 (en) Combination therapies
JP2025000632A (ja) 組み合わせ療法
CN118369119A (zh) KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法
CN118338904A (zh) KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
HK40059386A (zh) 组合疗法
CN120051282A (zh) 组合治疗
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109896

Country of ref document: HK